Sacituzumab govitecan shows clinically meaningful activity in real-world patients with metastatic TNBC and intracranial disease

Lymphoma

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ESMO 2025

Breast Cancer

ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab maintains QoL and delays functional decline in patients with PD-L1-positive metastatic TNBC

SABCS 2025

Breast Cancer

ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

Breast Cancer

Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entity

Clin Cancer Res

Davis AA, Jaeger E, Hagemann IS, Behdad A, Layng KV, Gerratana L, Mauer E, Shah AN, D'Amico P, Flaum L, Reduzzi C, Navo K, Gradishar WJ, Ahmed T, Chao C, Cristofanilli M

doi: 10.1158/1078-0432.CCR-25-0359

CHICAGO 2025

Breast Cancer

LBA109: ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1–positive metastatic TNBC

ESMO 2025

Breast Cancer

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

CHICAGO 2025

Breast Cancer

T-DXd rechallenge after grade 1 interstitial lung disease appears safe and clinically beneficial in a real-world setting

CHICAGO 2025

Genitourinary Cancer

Earlier initiation of ¹⁷⁷Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting

SPECIAL REPORT

Breast Cancer

Related content

Real-World Direct Comparison Shows Superiority of Axi-Cel over Liso-Cel in Patients with R/R LBCL

ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab maintains QoL and delays functional decline in patients with PD-L1-positive metastatic TNBC

ASCENT-03: Frontline sacituzumab govitecan improves QoL versus chemotherapy in patients with metastatic TNBC ineligible for PD-1/PD-L1 inhibitors

Molecular characterization of patients with metastatic invasive lobular carcinoma (ILC): using real-world data to describe this unique clinical entity

LBA109: ASCENT-04/KEYNOTE-D19: Sacituzumab govitecan plus pembrolizumab improves PFS in first-line PD-L1–positive metastatic TNBC

ASCENT-03: First-line sacituzumab govitecan improves PFS versus chemotherapy in patients with advanced TNBC ineligible for PD-1/PD-L1 inhibitors

T-DXd rechallenge after grade 1 interstitial lung disease appears safe and clinically beneficial in a real-world setting

Earlier initiation of 177Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting

Advances in HER2-Negative Breast Cancer Treatment: Insights from the PRIMED study

Earlier initiation of ¹⁷⁷Lu-PSMA-617 is associated with improved clinical outcomes in patients with mCRPC in a real-world setting